FATE THERAPEUTICS INC Proceeds from Convertible Debt
FATE THERAPEUTICS INC (FATE) reported Proceeds from Convertible Debt of $32.24 million for the 83-month period ending 2014-03-31, per its 10-Q filed 2014-05-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2016-03-03
- FATE THERAPEUTICS INC proceeds from convertible debt for the quarter ending 2013-12-31 was $0.00.
- FATE THERAPEUTICS INC proceeds from convertible debt for the quarter ending 2013-09-30 was $20.74M.
- FATE THERAPEUTICS INC proceeds from convertible debt for fiscal 2013 was $23.74M.
- FATE THERAPEUTICS INC proceeds from convertible debt for fiscal 2011 was $1.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month | Proceeds from Convertible Debt 77 month | Proceeds from Convertible Debt 80 month | Proceeds from Convertible Debt 83 month |
|---|---|---|---|---|---|---|---|
| 2014-03-31 | $32.24M 10-Q · filed 2014-05-13 | ||||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $20.74M derived: sum of 2 quarters · filed 2016-03-03 | $23.74M 10-K · filed 2016-03-03 | $32.24M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $20.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $23.74M 10-Q · filed 2014-11-12 | $32.24M 10-Q · filed 2013-11-13 | ||||
| 2013-06-30 | $3.00M 10-Q · filed 2014-08-12 | ||||||
| 2011-12-31 | $1.00M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |